Swiss Recommendations for Adult Cystic Fibrosis Care: Pathogenesis of CF by Koutsokera, Angela et al.
11. PATHOGENESIS OF CF
1. IntroductIon
jj Cystic fibrosis (CF) is an autosomal recessive genetic disorder (i.e. affected individuals 
carry mutations on both copies of the gene; carriers of a single mutation are asymptomatic). 
jj CF results from mutations of a single gene, the CF transmembrane conductance regula-
tor (CFTR) gene, situated on the long arm of chromosome 7. The CFTR gene encodes a 
transmembrane chloride (Cl-) channel which regulates water and ion transport across the 
surface of epithelial cells. 
jj The terms “mutation” and “polymorphism” are often incorrectly used to indicate 
“ disease-causing” and “neutral/benign” respectively, a practice that is misleading and 
should be avoided when possible. Formally, “mutation” simply indicates variation from the 
reference sequence without any indication of functional consequence or disease associa-
tion, whereas “polymorphism” designates a variant with an allelic frequency over 1% in the 
general population. the neutral term “variant” is now preferred in reporting labora-
tory results, accompanied by comments concerning the eventual association with 
disease. This convention will be followed in this document.
jj More than 2000 CFTR variants have been identified at different frequencies among diffe-
rent populations, but not all of them are CF-causing. For some variants the phenotypic 
repercussions are not clear and, in general, the link between genotype and clinical 
phenotype can be variable and unpredictable. 
js The spectrum of CF clinical phenotypes is wide and characterized by varying degrees 
of organ involvement, disease severity and progression rate. 
js The term CFTR-related disease (CFTR-RD) is used for clinical entities associated with 
CFTR dysfunction which do not fulfil the diagnostic criteria for CF.
jj The genetic laboratory should report on relevant identified variants and also whether they 
are: 
js CF-causing variants, predicted to be associated with CFTR residual function or not
js Variants of varying clinical consequences (VVCC)
js Variants of unknown significance (VUS)
Note: Variants which are likely to have no clinical relevance should generally not be 
reported.
jj Clinical severity depends on the residual CFTR activity. Modifier genes, such as TGF-β or 
Mannose Binding Lectin-2 (MBL2), may play a role in the clinical phenotype but cannot 
currently be used to make clinical predictions.
2. VarIant nomenclature (table 1)
jj Two nomenclature systems are in use 
js The traditional nomenclature system and
js The HGVS (Human Genome Variation Society) nomenclature
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jj The traditional system is commonly used and is generally easier to understand. It is used 
in this document for ease of reading. 
jj However, traditional nomenclature is imprecise and non-standardized and has led to  errors 
of testing or interpretation. All formal documents communicating genotypes (laboratory 
reports, clinical summaries and publications) should include HGVS coding of the variant, 
plus the traditional names if desired. 
 table 1: Examples of variant nomenclature (Adapted from1)
 cFtr testing result traditional nomenclature HGVS nomenclature
No variant detected Normal c.[=];[=]
i.e. “=” to the reference sequence
Heterozygote F508del/normal c.[1521_1523delCTT];[=] 
“[ ]” indicate the two alleles
One variant found in a 
probable compound 
heterozygote
F508del/unknown c.[1521_1523delCTT];[?]
Compound heterozygote F508del/621+1G>T c. [489+1G>T];[1521_1523delCTT]
in numerical order
Two variants, phase  
unknown
F508del and L138P c.413T>C(;)1521_1523delCTT, 
p.L138P(;)F508del
amino acid changes (p.) can 
 optionally be included
Heterozygote with two 
 variants on one allele
R117H-T5/normal c.[350G>A;1210-12T[5]];[=]
Intron 8 polyT variants* T5/T7 c.1210-12T[5];[7]
*See Section 7 of this chapter, “The particular case of IVS8 T5” 
3. cFtr VarIantS 
jj CFTR variants may be classified into four categories, according to their potential to cause 
disease (table 2, Figure 1)
a) cF-causing variants
b) Variants of varying clinical consequences (VVcc)
c) Variants of unknown significance (VuS)
d) Variants of no clinical consequences
jj It must be kept in mind that interpretation of clinically relevant genomic variation is parti-
cularly challenging. This is highlighted by the study of Sosnay et al. which assessed the 
disease liability of variants by studying 39.966 CF patients. In this population, 159 CFTR va-
riants had an allele frequency of ≥0.1% and only 127 (80%) met both clinical and functional 
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 table 2:  Common CFTR variants classified according to their disease-causing 
potential (adapted from2)
clinical phenotype
examples of variants
consistent effects Inconsistent effects*
CF-causing F508del
G542X, G551D, R553X, 1717-1G>A, 
W1282X, 3905insT, N1303K
L206W 
T5(TG13) 
D1152H
R117H
CFTR-related disease T5(TG12), V562I, L997F L206W
T5(TG13) 
D1152H 
T5(TG11) 
R117H
No clinical consequences I148T, V470M, F508C, S1235R T5(TG11) 
R117H
* Note that some variants (last column) can have very inconsistent effects; for example: 
- D1152H can be CF-causing or associated with CFTR-RD
- R117H can be either associated with CF, CFTR-related disease or have no clinical consequences
Discovered CFTR variants  
(N>2000) 
Variants of unknown significance - VUS 
(N=unknown) 
CF-causing  variants  (N=336) 
Variants of varying clinical 
consequences - VVCC 
(N=unknown) No clinical  
manifestations  
CFTR-related 
disease  
Cystic 
Fibrosis 
Variants of no clinical consequences 
(N=unknown) 
Figure 1: CFTR variants discovered (until August 2018) and vtheir clinical signifi-
cance. Of note that some variants have very inconsistent effects and the overlap of 
cycles can be even greater that the one depicted here, as for example in the case 
of R117H which can be found in CF, CFTR-related disease or in patients with no 
clinical manifestations.
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criteria consistent with disease. For the remaining variants, assessment of disease pene-
trance (i.e. proportion of people with a given genotype who exhibited symptoms of CF) led 
to their characterization as either neutral or indeterminate.
jj It is recommended to study the literature for reliable data on the implication of specific CF 
variants; information can also be found in the following sites:
https://cftr.iurc.montp.inserm.fr/cftr/
http://www.genet.sickkids.on.ca/app 
http://www.cftr2.org/index.php
http://www.umd.be/CFTR/W_CFTR/gene.html
4. cF-cauSInG VarIantS
jj For a variant to be considered CF-causing, one of the criteria presented in table 3 must 
be fulfilled. 
 table 3: Criteria for a variant to be considered CF-causing
Variant severely affects CFTR synthesis or function by changing the amino-acid sequence
Variant introduces a premature termination signal (insertion, deletion or nonsense variants)
Variant alters the ‘invariant’ nucleotides of intron splice sites
Variant predicted to modify the protein sequence, identified as the only change on one allele in 
a CF patient, after complete gene sequencing. 
jj the classes of cF-causing variants: Not all CF variants affect CF function to the same 
degree. The effect of a ‘CF-causing variant’ on the CFTR protein has been used to catego-
rize a variant in one of six classes (Figure 2, table 4). 
js Taking into account the new drugs targeting the molecular defect in CF, the classic 
classes of CF-causing variants are expected to evolve. Recently two modified classifi-
cations of the traditional class I CF-causing variants have been proposed: a) to include 
in Class I only those variants associated with “no synthesis of the CFTR protein” and to 
create a new Class for variants associated with “no mRNA transcription” (traditionally 
also included in class I), b) to divide Class I variants into Class IA (no mRNA) and Class 
IB (no CFTR protein). 
js Moreover, it has been recognized that a single ‘CF-causing variant’ may lead to combi-
national defects of the cFtr channel. For example, F508del causes a combination 
of class II, III and VI defects, this being the rationale behind the use of combinational 
therapies for homozygous F508del patients. More specifically, F508del impairs confor-
mational maturation (folding defect) resulting in premature degradation and decreased 
transport of the protein to the apical cell membrane (class II). The CFTR protein which 
escapes degradation and reaches the apical cell membrane also exhibits a channel 
gating defect (class III) and a stability defect resulting in increased turnover (class IV) 
(Figure 3).
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Figure 2: Classes of CF-causing variants
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5. VarIantS aSSocIated wItH cFtr-related dISeaSe
jj Several clinical entities associated with CFTR dysfunction do not fulfil the diagnostic criteria 
for CF. These are commonly but not always, single-organ disease phenotypes and are 
called CFTR-related disease or disorder (CFTR-RD) (see also chapter “diagnosis in 
adults”). 
jj The best-recognized forms of CFTR-RD are: 
js congenital bilateral absence of the vas deferens (CBAVD) 
js acute recurrent or chronic pancreatitis 
js diffuse bronchiectasis
jj It is not possible to predict clinical manifestations based uniquely on genotype data. As 
shown in table 2, some variants have varying clinical consequences and can be asso-
ciated with CFTR-RD, CF or no disease. 
6. comPlex alleleS
jj As CF is an autosomal recessive disease, patients must have disease-causing variants 
on both copies (alleles) of their CFTR gene (one inherited from the mother, one from the 
father). Typically, there is only one disease-causing variant per allele. 
Figure 3: refined classification of cF variants accounting for complex 
phenotypes of major cFtr according to variant class. Venn diagram indicating 
all combinations of mutation classes with examples (republished with permission 
of the American Society for Cell biology, from Veit et al. 2016 Ref3, permission 
conveyed through Copyright Clearance Center, Inc). Note: ∆F508 refers to F508del. 
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jj Some rare patients have not two but three or more variants. For example a patient affected 
with CF may have received one mutated allele from the father and two or three from the 
mother, in “cis” on a complex allele (Figure 5). 
Father
[F508del];[=]
Mother
[R74W;D1270N];[=]
Child
[F508del]; [R74W;D1270N]
Figure 5: In this example case, the girl affected with CF has received one mutated 
allele from each parent: F508del from her father and a complex allele with two 
variants from her mother. 
jj One consequence of the existence of complex alleles is that it is not always sufficient to 
find two CFTR variants to confirm a diagnosis: ideally it should be proven, by studying the 
parents, that the variants are on separate alleles (in “trans”) but in some cases it can be 
probabilistic (e.g. F508del and R117H are essentially certain to be in trans).
jj When the two variants are on the same parental CFTR allele (in “cis”) and not on different 
alleles (in “trans”), the diagnosis of CF cannot be established by this genetic test result. In 
such a case, it is necessary to search for another variant, located in trans, for example by 
sequencing the entire gene. 
7. tHe PartIcular caSe oF Intron VarIant Sequence 8 “IVS8 t5”
jj This variant concerns a region inside the CFTR gene which controls mRNA splicing, and 
indirectly controls the amount of functional CFTR protein produced. 
jj The CFTR locus in humans has a variable number (9–13) of TG repeats followed by a po-
lythymidine tract (poly T tract) of 5, 7, or 9 Ts in intron 8 (Figure 6).
jj Shorter polyT tracts are associated with lower levels of correctly-spliced mRNA, and lower 
quantities of functional CFTR protein in the cell. 
js T9 and T7 tracts have no pathological consequences as the amount of mRNA results in 
sufficient CFTR function, whereas 
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Figure 6: the particular case of “IVS8 t5” A) The TGmTn variant sequence in 
intron 8 (“IVS8”) of the CFTR gene. The example would be traditionally described 
as “IVS8 T5(TG11)”. B) Consequences of the TGmTn variants. Shorter T tracts are 
associated with defective splicing of RNA, leading to a reduced quantity of CFTR 
protein; Longer TG tracts aggravate this effect and modulate the severity of the T5 
effect. T5, in the presence of another CF-causing variant in trans, may result in CF 
(e.g. F508del/5T). The combination of 5T in cis with R117H is considered a  
CF-causing variant (although it can result in a sweat Cl- test <60mmol/l).
js T5 tracts result in more significant reduction in CFTR function which
 – can have no consequence OR
 – can result in CFTR-RD OR even
 – in the presence of another CF-causing variant in trans, they can be associated with 
CF. Usually there is residual CFTR function, e.g. pancreatic sufficient CF.
jj The number of TG repeats immediately adjacent to 5T correlates with exon 9 skipping and 
abnormal splicing. Transcripts bearing more TG repeats increase the penetrance of 5T.
8. Structure oF normal cFtr
jj CFTR is a member of the ABC (ATP-Binding Cassette) proteins. It is comprised of 1480 
amino-acids and it is expressed in the apical cell membranes of epithelial cells.
jj CFTR structure (Figure 7) 
js Two regions of six membrane-spanning domains (MSD-1 and MSD-2): they form the 
Cl-/HCO3
- channel.
js Two nucleotide-binding domains (NBD-1, NBD-2): they mediate ATP hydrolysis hence 
regulating the opening and closing of the channel.
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9. FunctIon oF cFtr 
jj CFTR is present at the apical membrane of the epithelial cells. It is expressed throughout 
the body and has a role in the function of many organs. 
jj The main function of CFTR is that of an apical epithelial cl- channel (Figures 8-10); 
however its role is multifaceted and extends beyond Cl- transport.
jj cFtr regulates/influences
js HCO3
- transport (e.g. CFTR secretes HCO3
- but also regulates the function of SLC26A 
anion transporters such as Cl-/HCO3
-  exchanger): this mechanism plays an important 
role on fluid transport not only in the pancreatic ducts and the gastrointestinal tract but 
also in the lung.
js The pH of airway surface liquid
js Water transport: fluid transport is driven by active Cl- transport (in the lungs) or by HCO3
- 
transport (in the pancreas, duodenum).
Figure 7: Structure of the normal CFTR 
NBD-1
MSD-1
NBD-2
Regulatory
domain
Regulatory
domain
MSD-2 Cellular
membrane
NBD-1 NBD-2
Ductal lumen
Interstitium
js R domain: its phosphorylation allows the opening of the channel.
js The PDZ domain at the C-terminus region: is required for the polarization of CFTR to the 
apical plasma membrane.
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js Epithelial sodium channels (ENaC): It consists of four subunits (two alpha, one beta 
and one gamma). ENaC regulation by CFTR is not fully elucidated, but appears to play 
major role in CF. when the nbd-1 region of cFtr is active, it has an inhibitory 
effect on enac. 
js Other chloride channels [e.g. SLC26A9, TMEM16A, CaCC which is a Ca2+ regulated 
Cl- conductance, ORCC (Outward Rectifying Cl- Channels) which is a cAMP regulated 
Cl- conductance]
js Potassium channels (e.g. ROMK+)
js The secretion of other anions (e.g. glutathione, thiocyanate)
js The production of mucins
js CFTR regulates the sweat Cl¯ absorption and the β-adrenergic sweat secretion (but not 
the cholinergic sweat secretion) (Figure 9).
Figure 8: cFtr-regulated sweat chloride absorption in a) a healthy sweat 
duct, b) a cF sweat duct
CFTR
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10. dySFunctIon oF cFtr 
jj In the sweat glands (Figures 8 and 9): 
js Sweat cl- absorption: Abnormal CFTR → decreased reabsorption of Cl- from 
the  ductular lumen into the interstitium, while there is an excessive Na+ transport 
in the interstitium through other channels → the ductal lumen becomes more 
negative than the  interstitium (elevated transepithelial potential difference) → 
12 1. PATHOGENESIS OF CF
decreased total NaCl flux into the interstitium → high concentration of NaCl in the sweat 
of CF patients and increased transepithelial potential difference (phenomena used for 
diagnostic purposes). 
js Sweat secretion (Figure 9): Abnormal CFTR → reduced β-adrenergic sweat produc-
tion →  reduced volume of sweat in CF (phenomenon used for diagnostic purposes). 
jj Note: during the sweat Cl- test, application of pilocarpine stimulates the cholinergic sweat 
production (which is unaffected by CFTR). This leads to the production of sweat, used for 
the subsequent measurement of the Cl- concentration (which is affected by CFTR). During 
Figure 9: CFTR regulates the sweat Cl- absorption and the β-adrenergic sweat 
secretion (but not the cholinergic sweat secretion). 
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the β-adrenergic sweat secretion test the mean maximal β-adrenergically stimulated sweat 
rate (which is affected by CFTR) is measured (see chapter “diagnosis in adults”).
jj In the lungs (Figure 10):
js The airway surface liquid (ASL) contains two aqueous layers:
1. Mucus layer containing gel-forming mucins
2. Periciliary layer (PCL): which provides the microenvironment of beating cilia; it lubri-
cates their movement and prevents mucus adhesion. 
js the low-volume model is currently the favoured model: it postulates that the normal 
ASL has salt levels similar to those of plasma. This model emphasizes the hyperactiva-
tion of ENaC in the absence of CFTR, the activation of non-CFTR Cl- pathways and the 
decreased secretion of HCO3-.
 – Abnormal CFTR → hyperactivation of ENaC → Na+ hyperabsorption into the inters-
titium → increased transepithelial potential difference (airway lumen more negative 
than interstitium) → relative increase of Cl- permeability into the interstitium through 
non-CFTR pathways → net increase in the absorption of NaCl → osmotic increase 
Figure 10: Function of cFtr in the airway epithelium of a) healthy airway 
and b) cF airway. In the healthy lung the direction of Cl- movement through 
CFTR depends on its level of activation: at a low level of activation CFTR absorbs 
Cl- in the interstitium whereas at a high level of activation CFTR secretes Cl- in the 
airway lumen. In CF, the currently favored model emphasizes the hyperactivation 
of ENaC, the activation of non-CFTR Cl- pathways and the decreased secretion of 
HCO3
- leading to low airway surface liquid pH.
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of water absorption into the interstitium → dehydration, depletion of volume of the 
airway-surface fluid, viscous and adherent mucous → abnormal mucociliary clea-
rance → inflammation, bacterial infection → tissue destruction. 
 – Abnormal CFTR → abolition of HCO3
- secretion through CFTR and dysfunction of Cl-/
HCO3
- exchanger → decreased secretion of HCO3
- in the airway lumen →  decreased 
airway pH → decreased activity of antimicrobial peptides and further  hyperactivation 
of ENaC → inflammation, bacterial infection → tissue destruction.
jj In the pancreas: 
js Abnormal CFTR → reduced HCO3
- secretion from the pancreatic duct cells into the  lumen 
→ pancreatic enzyme precipitation, mucus accumulation → reduction of pancreatic 
enzyme delivery to the duodenum → pancreas destruction (exocrine and endocrine 
pancreatic insufficiency).
11. mecHanISmS ImPlIcated In cF
jj as described above, the 2 main mechanisms are a) the abnormal NaCl and fluid 
transport across the epithelial surface leading to the production of mucus with abnormal 
properties (mucus plugging) and b) decreased pH of the airway-surface liquid leading to 
antimicrobial activity impairment. 
jj additional mechanisms:
js Defective mucin unfolding: mucins are glycoproteins which are the main component of 
mucous. They are packed in the granulae of goblet cells with hydrogen ions and Ca+2 
and unfold upon release on the mucosal surface. Bicarbonate secreted through CFTR 
contributes to the unfolding of mucins by increasing the pH and by chelating Ca+2. 
This mechanism is impaired in CF leading to defective mucin unfolding and mucous 
plugging.
js Concomitant host-defense defects resulting in increased levels of IL-8, IL-6. TNFα and 
LTB4, reduced levels of anti-inflammatory cytokines.
js Oxidant/antioxidant imbalance.
js Animal studies suggest that infants with CF may have congenital airway defects, contri-
buting to disease progression (e.g. air trapping due to a structural airway abnormalities).
js Impaired airway surfactant function.
jj The diversity of mechanisms and of effects of CFTR defects contribute to a vicious cycle 
and sustained disease/complexity of treatment. 
12. tHe SPectrum oF clInIcal manIFeStatIonS oF cF
jj CFTR is expressed in epithelia throughout the body and its absence or malfunction may 
lead to a large spectrum of clinical manifestations (Figure 11). 
jj CFTR genotype and CF phenotype associations are often discordant, and for that reason 
the genotype cannot predict the clinical course of individual patients. 
jj The clinical phenotype (type and number of affected organs, severity of the disease, age 
of onset) depends on genetic CFTR and non CFTR modifiers, environmental factors and 
treatment. 
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Figure 11: Organs affected by CFTR dysfunction and manifestations of CF 
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